Changes

no edit summary
Line 2,583: Line 2,583:  
|Astrocystoma, IDH-Mutant
 
|Astrocystoma, IDH-Mutant
 
|Disease
 
|Disease
 +
|Riley Lochner (trainee), Shashi Shetty (mentor)
 +
|3/3/2022
 
|
 
|
 +
|PENDING
 
|
 
|
 +
|Laveniya Satgunaseelan (LS)
 
|
 
|
|
+
|2021 template added
|
  −
|
  −
|
  −
|
   
|-
 
|-
|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted||Disease||
+
|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted||Disease||Riley Lochner (trainee), Shashi Shetty (mentor)
|
+
|3/3/2022
|
  −
|
  −
|
   
|
 
|
 +
|PENDING
 
|
 
|
 +
|Laveniya Satgunaseelan (LS)
 
|
 
|
 +
|2021 template added
 
|-
 
|-
 
|Glioblastoma, IDH-Wildtype||Disease||
 
|Glioblastoma, IDH-Wildtype||Disease||
Line 2,646: Line 2,646:  
|
 
|
 
|-
 
|-
|Diffuse Midline Glioma, H3  K27-Altered||Disease||
+
|Diffuse Midline Glioma, H3  K27-Altered||Disease||Laveniya Satgunaseelan (Linda Cooley - previous version)
|
  −
|
  −
|
   
|
 
|
 
|
 
|
 +
|PENDING
 
|
 
|
 +
|LS
 
|
 
|
 +
|2021 template added
 
|-
 
|-
|Diffuse Hemispheric Glioma, H3 G34-Mutant||Disease||
+
|Diffuse Hemispheric Glioma, H3 G34-Mutant||Disease||Xiaolin (Lynn) Hu
|
+
|2/21/2022
|
  −
|
  −
|
   
|
 
|
 +
|PENDING
 
|
 
|
 +
|LS
 
|
 
|
 +
|2021 template added
 
|-
 
|-
|Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype||Disease||
+
|Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype||Disease||Madina Sukhanova
|
+
|10/28/2022
|
  −
|
  −
|
   
|
 
|
 +
|PENDING
 
|
 
|
 +
|LS
 
|
 
|
 +
|2021 template added
 
|-
 
|-
 
|Infant-Type Hemispheric Glioma||Disease||
 
|Infant-Type Hemispheric Glioma||Disease||
Line 2,680: Line 2,680:  
|
 
|
 
|
 
|
|
+
|2021 template added
 
|-
 
|-
|Pilocytic Astrocytoma||Disease||
+
|Pilocytic Astrocytoma||Disease||Jeremy Pulvers
|
+
|9/13/2022<br />
|
  −
|
  −
|
   
|
 
|
 +
|PENDING
 
|
 
|
 +
|LS
 
|
 
|
 +
|2021 template added
 
|-
 
|-
 
|High-Grade Astrocytoma with Piloid Features||Disease||
 
|High-Grade Astrocytoma with Piloid Features||Disease||
Line 2,736: Line 2,736:  
|
 
|
 
|-
 
|-
|Ganglioglioma||Disease||
+
|Ganglioglioma||Disease||Leila Moayed-Aloei
|
+
|6/30/2022
|
  −
|
  −
|
   
|
 
|
 +
|COMPLETE
 
|
 
|
 +
|LS
 
|
 
|
 +
|2021 template added
 
|-
 
|-
 
|Gangliocytoma||Disease||
 
|Gangliocytoma||Disease||
Line 2,979: Line 2,979:  
|
 
|
 
|-
 
|-
|Medulloblastoma, WNT-Activated||Disease||
+
|Medulloblastoma, WNT-Activated||Disease||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|
+
|9/20/21
|
  −
|
  −
|
  −
|
   
|
 
|
 +
|COMPLETE
 
|
 
|
 +
|Holli Drendel (interim)/Laveniya Satgunaseelan (LS)
 +
|9/22/2022
 +
|2021 template added
 
|-
 
|-
 
|Medulloblastoma, SHH-Activated and TP53-Wildtype||Disease||
 
|Medulloblastoma, SHH-Activated and TP53-Wildtype||Disease||